TIDMSAR
Sareum Holdings PLC
09 October 2017
(AIM: SAR) 9 October 2017
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Sierra Oncology to host Key Opinion Leader Meeting "Beyond PARP:
The Clinical Potential of Next Generation DNA Damage Response (DDR)
Therapeutics" on October 12th in NY
Sareum Holdings plc (AIM: SAR), the specialist cancer drug
discovery and development business, notes that Sierra Oncology, the
licence holder advancing clinical cancer candidate SRA737, will
host a Key Opinion Leader (KOL) luncheon on the topic of "Beyond
PARP: The Clinical Potential of Next Generation DNA Damage Response
Therapeutics" on Thursday, October 12 from 12:00-13:30hrs EST in
New York, USA.
The meeting will feature presentations by three KOLs in DDR
scientific and clinical development:
-- Leonard Post, PhD, Chief Scientific Officer of Vivace
Therapeutics; former CSO of BioMarin Pharmaceutical, will discuss
lessons learned from PARP inhibitor development, with a focus on
optimizing drug properties;
-- Eric J. Brown, PhD, Associate Professor of Cancer Biology at
the Perelman School of Medicine of the University of Pennsylvania,
will discuss the ATR/Chk1 pathway and its biology, highlighting
emerging views on the importance of replication stress;
-- Geoffrey I. Shapiro, MD, PhD, Associate Professor of Medicine
at Harvard Medical School; Clinical Director at the Center for DNA
Damage and Repair, and Director of the Early Drug Development
Center at Dana-Farber Cancer Institute, will discuss translating
emerging DDR science into the cancer clinic, emphasizing the
importance of patient selection strategies.
In addition to the KOL presentations, Dr. Nick Glover, President
and CEO of Sierra Oncology, will provide a brief overview on the
company's ongoing clinical development program for SRA737, a
potent, highly selective, orally bioavailable small molecule
inhibitor of the emerging DDR target, Chk1.
Following the presentation, the KOLs, along with members of
Sierra's Senior Management team, will be available to answer
questions.
A live webcast of the event and replay will be accessible
here:
Webcast: www.sierraoncology.com
Direct link: http://lifesci.rampard.com/20171012/
About the Key Opinion Leaders
Leonard Post, PhD, is Chief Scientific Officer of Vivace
Therapeutics and also serves as an advisor to numerous
biotechnology companies and to venture investors. Until July 2016,
he was Chief Scientific Officer of BioMarin Pharmaceutical, and
before that was CSO and cofounder of LEAD Therapeutics which was
acquired by BioMarin in 2010. His work in DNA repair involved the
discovery of the PARP inhibitor talazoparib at LEAD and its
development into Phase 3 at BioMarin. Talazoparib is currently
being tested in EMBRACA, a Phase III clinical study in gBRCA+
locally advanced and/or metastatic breast cancer. From 2000-2006,
he was Senior Vice President of Research and Development at Onyx
Pharmaceuticals, during the clinical development of Nexavar from
IND through NDA approval. Prior to Onyx, he was at Parke-Davis
Pharmaceutical where he was VP of Discovery Research; and before
that at The Upjohn Company in several positions. Dr. Post is
currently a member of the board of directors of Viralytics Ltd., an
Australian Stock Exchange-listed company; and of private companies
Orphagen Pharmaceuticals, Fedora Pharmaceuticals and Oxyrane
Ltd.
Eric J. Brown, PhD is an Associate Professor of Cancer Biology
at the Perelman School of Medicine at the University of
Pennsylvania. Dr. Brown's laboratory examines how signaling
maintains genome stability during DNA synthesis and how this
function is essential to cancer cells. His laboratory was the first
to report that oncogenic stress is sufficient to cause selective
sensitivity to ATR inhibition. Dr. Brown's laboratory is currently
identifying predictive biomarkers of therapeutic benefit and the
mechanisms of action of these drugs through a combination of
genome-wide breakpoint mapping and replication fork proteomics. In
collaboration with clinical researchers, these biomarkers of
response will be exploited in current and future clinical trials.
Collectively, the Brown laboratory seeks both to define the
mechanisms of action of ATR/Chk1 inhibitors and to identify their
optimal uses in cancer therapies. Dr. Brown received his PhD
(Immunology) from Harvard University in 1996. He performed his
doctoral research with Dr. Stuart Schreiber at Harvard University,
where he purified and cloned the mammalian target of rapamycin
(mTOR). In his postdoctoral research in Dr. David Baltimore's
laboratory at the California Institute of Technology, Dr. Brown
investigated the impact of ATR suppression on genome stability and
checkpoint signaling in response to replication stress.
Geoffrey I. Shapiro, MD, PhD is an Associate Professor of
Medicine at Harvard Medical School and Director of the Early Drug
Development Center at Dana-Farber Cancer Institute. Dr. Shapiro
runs one of the largest Phase 1 clinical trials programs in the
United States and dedicates his time to developing leading cancer
treatments. He is also a member of Dana-Farber's Thoracic Oncology
Program and a member of the Dana-Farber/Harvard Cancer Center SPORE
(Specialized Program of Research Excellence) in Lung Cancer. Dr.
Shapiro conducts both basic and translational research on
cyclin-dependent kinase inhibitors, with a focus on defining the
role of these inhibitors in the cellular response to DNA damage.
Dr. Shapiro received his PhD in 1987 and his MD in 1988 from
Cornell University, followed by postgraduate training in internal
medicine at Beth Israel Hospital, Boston. He completed a fellowship
in medical oncology at Dana-Farber Cancer Institute, during which
he investigated the role of cell-cycle-related proteins in lung
cancer. He joined the Dana-Farber faculty in 1994.
The Press release from Sierra Oncology can be found by clicking
here
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser and
Co-Broker)
Chris Fielding / James Sinclair-Ford 020 7220 1666
Hybridan LLP (Co-Broker)
Claire Noyce 020 3764 2341
Citigate Dewe Rogerson (Media
enquiries)
Shabnam Bashir/ Mark Swallow/
David Dible 020 7282 9571
Notes for editors:
Sareum is a specialist drug discovery and development company
delivering targeted small molecule therapeutics, focusing on cancer
and autoimmune disease, and generating value through licensing them
to international pharmaceutical and biotechnology companies at the
preclinical or early clinical trials stage.
Its most advanced programme, SRA737, is a novel Checkpoint
kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology
and in clinical trials targeting a range of advanced cancers. The
key role of Chk1 in cancer cell replication and DNA damage repair
suggests that SRA737 may have broad application as a targeted
therapy in combination with other oncology and immune-oncology
drugs in genetically defined patients.
Sareum is also advancing programmes to develop novel tyrosine
kinase 2 (TYK2) inhibitors in autoimmune diseases and cancers, and
Aurora+FLT3 inhibitors in haematological cancers, which are in the
IND-enabling preclinical and lead optimisation stages.
The Company's drug discovery technology platform (SKIL(R) -
Sareum Kinase Inhibitor Library) is being applied to generate drug
research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit www.sareum.co.uk
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAZMMGGLLDGNZG
(END) Dow Jones Newswires
October 09, 2017 07:00 ET (11:00 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024